FDA-approved test for routine cervical cancer screening in individuals ≥25 years with a cervix. Follow-up test for abnormal cytology results in individuals ≥21 years with a cervix.
Qualitative Polymerase Chain Reaction
Mon, Wed, Fri
New York DOH Approval Status
Cervical, anal or vaginal specimens with SurePath collection kit and place in SurePath media.
Transport original SurePath or briefly vortex and transfer 3 mL to an ARUP Standard Transport Tube. (Min 1.5 mL)
Bloody or dark brown specimens. Specimens in any media other than indicated above.
Specimen source required.
Ambient: 1 month; Refrigerated: 6 months; Frozen: Unacceptable
This test amplifies DNA of HPV16, HPV18 and 12 other high-risk HPV types (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) associated with cervical cancer and its precursor lesions. Sensitivity may be affected by specimen collection methods, stage of infection, and the presence of interfering substances. Results should be interpreted in conjunction with other available laboratory and clinical data. A negative high-risk HPV result does not exclude the presence of other high-risk HPV types.
HPV testing should not be used for screening or management of atypical squamous cells of undetermined significance (ASCUS) in women under age 21.
Depends on Specimen/Source/Method
For cervical sources, a negative high-risk HPV result does not exclude the possibility of future cytologic abnormalities, underlying CIN2-3, or cancer.
|Component Test Code*||Component Chart Name||LOINC|
|2011934||HPV Genotype 18 by PCR||77400-0|
|2011935||HPV Genotype 16 by PCR||77399-4|
|2011936||HPV, Other High Risk by PCR||82675-0|
- HPV 16 18
- HPV SurePath
- HPV Typing
- Human papilloma virus